Eugia Pharma receives USFDA Approval for Bortezomib for Injection

Business Featured Posts Health National Top Stories Trending TS News
Spread the News online news,India, May 4, 2022: Aurobindo Pharma Limited is pleased to announce that its wholly owned subsidiary company, Eugia Pharma Specialties Limited, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bortezo mib for injection, 3.5 mg. Bortezomib for Injection, 3.5 mg/vial (Single-Dose Vial) to be bioequivalent and therapeutically equivalent to the Velcade for Injection 3.5 mg/vial, of Takeda Pharmaceuticals U.S.A. Inc. The product is being launched immediately.

The approved product has a market size of US$ 1172 million for the twelve months ending March 2022, according to IQVIA. This is the 136 th ANDA (including 7 tentative approvals) to be out of Eugia Pharma Specialty
Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Bortezomib for injection is indicated for the treatment of
 Adult patients with multiple myeloma (cancer of plasma cells)
 Also used to treat adult patients with mantle cell lymphoma (cancer of lymph nodes)